Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Inan

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Acta Oncologica (Stockholm, Sweden)|October 2, 2025
Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based studyAli Inan El-Naggar, Andreas Karakatsanis, Antonios Valachis
Advances in Database Technology : Proceedings. International Conference on Extending Database Technology|February 7, 2014
Efficient Privacy-Aware Record IntegrationMehmet Kuzu, Murat Kantarcioglu, Ali Inan, et al.
JCO Oncology Practice|February 9, 2026
Influenza Vaccination Among Patients With Cancer Treated With Checkpoint Inhibitors: Association With Survival Outcomes and Immune-Related Adverse EventsAnthoula Koliadi, Evangelos Digkas, Ali Inan El-Naggar, et al.
Pigment Cell & Melanoma Research|December 29, 2023
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysisViktoria Rydén, Ali Inan El-Naggar, Anthoula Koliadi, et al.
Cancer Medicine|May 3, 2023
Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort studyCecilia Olsson Ladjevardi, Anthoula Koliadi, Viktoria Rydén, et al.
Frontiers in Oncology|July 11, 2024
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectivenessCecilia Olsson Ladjevardi, Anthoula Koliadi, Viktoria Rydén, et al.
Environmental Science and Pollution Research International|September 23, 2025
Ranking circularity levels in industrial parks: a holistic approach incorporating environmental, economic and social indicatorsIstemi Berk, Volkan Ş Ediger, Engin Bağış Öztürk, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2024
Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancerCecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, et al.
Journal of the National Cancer Institute|January 22, 2025
Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementationIoannis Zerdes, Panagiotis Filis, Georgios Fountoukidis, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Acta Oncologica (Stockholm, Sweden)|October 2, 2025
Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based studyAli Inan El-Naggar, Andreas Karakatsanis, Antonios Valachis
Advances in Database Technology : Proceedings. International Conference on Extending Database Technology|February 7, 2014
Efficient Privacy-Aware Record IntegrationMehmet Kuzu, Murat Kantarcioglu, Ali Inan, et al.
JCO Oncology Practice|February 9, 2026
Influenza Vaccination Among Patients With Cancer Treated With Checkpoint Inhibitors: Association With Survival Outcomes and Immune-Related Adverse EventsAnthoula Koliadi, Evangelos Digkas, Ali Inan El-Naggar, et al.
Pigment Cell & Melanoma Research|December 29, 2023
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysisViktoria Rydén, Ali Inan El-Naggar, Anthoula Koliadi, et al.
Cancer Medicine|May 3, 2023
Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort studyCecilia Olsson Ladjevardi, Anthoula Koliadi, Viktoria Rydén, et al.
Frontiers in Oncology|July 11, 2024
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectivenessCecilia Olsson Ladjevardi, Anthoula Koliadi, Viktoria Rydén, et al.
Environmental Science and Pollution Research International|September 23, 2025
Ranking circularity levels in industrial parks: a holistic approach incorporating environmental, economic and social indicatorsIstemi Berk, Volkan Ş Ediger, Engin Bağış Öztürk, et al.
Cancer Immunology, Immunotherapy : CII|November 7, 2024
Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancerCecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, et al.
Journal of the National Cancer Institute|January 22, 2025
Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementationIoannis Zerdes, Panagiotis Filis, Georgios Fountoukidis, et al.
Pageof 1